Abstract
A study of 103 2nd diabetes mellitus inpatients was carried out with the help of the composite test (clinical scales TSS and NIS LL + 7 EMG-characteristics of the leg peripheral nerves’ state) for diagnosing and establishing stages of diabetic polyneuropathy. In 75% of patients distal symmetric sensor-motor diabetic polyneuropathy is detected, from them – in 33% subclinical stage. In 30 patients with subclinical stage of the diabetic polyneuropathy treatment by Actovegin® was conducted for 5 months: 10 infusions 250.00 ml of 20%-solution and then administration of Actovegin® tablets at a dosage 200 mg 3 tpd. At examination after the course of treatment improvement of the capillary blood flow, increase of density of thin fibers in epidermis and skin (punch-biopsy), content of endothelium in the skin, activation of neoanginesis. Discussing the literature data and own findings a conclusion about effectiveness of Actovegin® in the 2nd diabetes mellitus patients with polyneuropathy, including at a subclinical stage.
Highlights
Проведено обследование 103 стационарных больных сахарным диабетом 2-го типа с помощью композитного теста для выявления наличия и стадий диабетической полиневропатии
In 30 patients with subclinical stage of the diabetic polyneuropathy treatment by Actovegin® was conducted for 5 months: 10 infusions 250.00 ml of 20%-solution and administration of Actovegin® tablets at a dosage 200 mg 3 tpd
Treatment of symptomatic polyneuropathy with Аctovegin in type 2 diabetic patients
Summary
АКТОВЕГИН® В ЛЕЧЕНИИ СУБКЛИНИЧЕСКОЙ ДИСТАЛЬНОЙ СИММЕТРИЧНОЙ СЕНСОРНО-МОТОРНОЙ ПОЛИНЕВРОПАТИИ. Проведено обследование 103 стационарных больных сахарным диабетом 2-го типа с помощью композитного теста (клинические шкалы TSS и NIS-LL + 7 ЭМГ-характеристик состояния периферических нервов ног) для выявления наличия и стадий диабетической полиневропатии. Ключевые слова: сахарный диабет 2-го типа, распространенность диабетической полиневропатии, панч-биопсия, компьютерная капилляроскопия, эффективность лечения препаратом Актовегин®. In 75% of patients distal symmetric sensor-motor diabetic polyneuropathy is detected, from them – in 33% subclinical stage. In 30 patients with subclinical stage of the diabetic polyneuropathy treatment by Actovegin® was conducted for 5 months: 10 infusions 250.00 ml of 20%-solution and administration of Actovegin® tablets at a dosage 200 mg 3 tpd. Discussing the literature data and own findings a conclusion about effectiveness of Actovegin® in the 2nd diabetes mellitus patients with polyneuropathy, including at a subclinical stage. Количество больных СД с симптомной дистальной симметричной диабетической полиневропатией (ДПН) оценивалось в 30–40 млн.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
